<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04764682</url>
  </required_header>
  <id_info>
    <org_study_id>19-005445</org_study_id>
    <nct_id>NCT04764682</nct_id>
  </id_info>
  <brief_title>Determining Molecular Drivers of Radiation Dermatitis</brief_title>
  <official_title>Determining Molecular Drivers of Radiation Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being conducted to address key gaps in current knowledge and set the stage for&#xD;
      rational design of strategies to prevent (pre-exposure to radiation), mitigate (post-exposure&#xD;
      to radiation before overt signs/symptoms appear), and/or treat (post-onset of signs/symptoms)&#xD;
      radiation dermatitis (itchy, dry skin or a rash on swollen, reddened skin).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 10, 2021</start_date>
  <completion_date type="Anticipated">February 18, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 18, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in skin</measure>
    <time_frame>Baseline, final week of radiation</time_frame>
    <description>A skin punch biopsy will be obtained from a visible area of skin that harbors signs of clinical radiation.</description>
  </primary_outcome>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Breast Cancer</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Skin tissue. A 3mm punch biopsy will be collected at the time of surgery and during the final&#xD;
      week of radiation treatment. One half of the sample will be placed in a separate cryovial&#xD;
      container RNA later and the other half will be placed in a cryovial and flash frozen&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adult women aged 18 years and older&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients receiving standard-of-care postoperative radiation therapy (2-2.7 Gy per&#xD;
             fraction) to the breast and/or chest wall for breast cancer treatment.&#xD;
&#xD;
          -  Tissue diagnosis of breast cancer.&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  Signed informed consent.&#xD;
&#xD;
          -  Complete blood count within normal limits within the preceding 2 weeks.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Induction chemotherapy or biologic therapy&#xD;
&#xD;
          -  Concurrent chemotherapy or biologic therapy&#xD;
&#xD;
          -  Autoimmune disease with skin manifestations - psoriasis, dermatomyositis, scleroderma,&#xD;
             eczema, polymyositis&#xD;
&#xD;
          -  Allergy to lidocaine anesthesia&#xD;
&#xD;
          -  Known bleeding diathesis (anticoagulation with warfarin, coagulation/bleeding&#xD;
             disorders, vitamin C or K deficiency, thrombocytopenia)&#xD;
&#xD;
          -  History of keloids or easy scarring&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laura Vallow, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kayla M Rodriguez</last_name>
    <phone>904-953-3588</phone>
    <email>rodriguez.kayla1@mayo.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 18, 2021</study_first_submitted>
  <study_first_submitted_qc>February 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2021</study_first_posted>
  <last_update_submitted>February 18, 2021</last_update_submitted>
  <last_update_submitted_qc>February 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Laura A. Vallow</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Radiodermatitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

